Last updated on March 2019

Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM


Brief description of study

This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma following 1-4 lines of prior therapy. Patients will receive either melflufen+dexamethasone+bortezomib or melflufen+dexamethasone+daratumumab and are required to be PI refractory to be enrolled to the bortezomib regimen, and to not have any prior exposure to daratumumab or other antiCD-38 mAb to be enrolled to the daratumumab regimen.

Clinical Study Identifier: NCT03481556

Find a site near you

Start Over

Fakultn nemocnice Ostrava

Ostrava, Czechia
1.29miles
  Connect »